ID

34540

Beschreibung

Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02468284

Link

https://clinicaltrials.gov/show/NCT02468284

Stichworte

  1. 19.01.19 19.01.19 -
  2. 22.05.19 22.05.19 -
Rechteinhaber

see on clinicaltrials.gov

Hochgeladen am

19. Januar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Prostate Cancer NCT02468284

Eligibility Prostate Cancer NCT02468284

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
Beschreibung

ID.1

Datentyp

boolean

has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
Beschreibung

ID.2

Datentyp

boolean

has a screening serum testosterone level >150 ng/dl
Beschreibung

ID.3

Datentyp

boolean

has an eastern cooperative oncology group (ecog) score of ≤2
Beschreibung

ID.4

Datentyp

boolean

Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
Beschreibung

ID.5

Datentyp

boolean

is currently treated with a 5-alpha reductase inhibitor
Beschreibung

ID.6

Datentyp

boolean

is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
Beschreibung

ID.7

Datentyp

boolean

is in need of neoadjuvant hormonal therapy
Beschreibung

ID.8

Datentyp

boolean

has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
Beschreibung

ID.9

Datentyp

boolean

Ähnliche Modelle

Eligibility Prostate Cancer NCT02468284

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
boolean
ID.2
Item
has a prostate-specific antigen (psa) level ≥2.0 ng/ml at screening
boolean
ID.3
Item
has a screening serum testosterone level >150 ng/dl
boolean
ID.4
Item
has an eastern cooperative oncology group (ecog) score of ≤2
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
boolean
ID.6
Item
is currently treated with a 5-alpha reductase inhibitor
boolean
ID.7
Item
is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
boolean
ID.8
Item
is in need of neoadjuvant hormonal therapy
boolean
ID.9
Item
has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
boolean

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video